DNAY - Codex DNA, Inc. Stock Price, Fair Value and News

0.35USD0.00 (0.00%)Market Closed

Market Summary

USD0.350.00

Market Closed

0.00%

DNAY Stock Price

View Fullscreen

DNAY RSI Chart

DNAY Valuation

Market Cap

10.5M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.38

EV/EBITDA

-0.33

Price/Free Cashflow

-0.29

DNAY Price/Sales (Trailing)

DNAY Profitability

Operating Margin

61.62%

EBT Margin

-173.40%

Return on Equity

-20.1K%

Return on Assets

-67.78%

Free Cashflow Yield

-347.82%

DNAY Fundamentals

DNAY Revenue

Revenue (TTM)

27.5M

Rev. Growth (Yr)

-26.32%

Rev. Growth (Qtr)

25.4%

DNAY Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-117.5%

Earnings Growth (Qtr)

-66.37%

Breaking Down DNAY Revenue

Last 7 days

9.4%

Last 30 days

-20.4%

Last 90 days

6.1%

Trailing 12 Months

-70%

How does DNAY drawdown profile look like?

DNAY Financial Health

Current Ratio

3.71

Debt/Equity

22.14

Debt/Cashflow

-6.58

DNAY Investor Care

Shares Dilution (1Y)

1.36%

Diluted EPS (TTM)

-1.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	28.1M	31.1M	30.0M	27.5M
2022	14.4M	17.2M	21.0M	27.4M
2021	7.7M	8.8M	9.9M	11.0M
2020	0	0	0	6.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Codex DNA, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 11, 2022	nelson todd robert	bought	191,542	1.5634	122,516	president & ceo
Jul 20, 2022	tumolo annette	acquired	-	-	74,611	-
Jun 09, 2022	nachtsheim jami k	acquired	-	-	20,630	-
Jun 09, 2022	tsingos christine a	acquired	-	-	20,630	-
Jun 09, 2022	snider william	acquired	-	-	20,630	-
Jun 09, 2022	witney frank	acquired	-	-	20,630	-
Jun 09, 2022	jackson andrea liapis	acquired	-	-	20,630	-
Jun 22, 2021	danaher corp /de/	acquired	-	-	2,294,160	-
Jun 22, 2021	snider william	acquired	-	-	1,319,040	-
Jun 22, 2021	broadoak fund iv, llc	acquired	-	-	1,319,040	-

Which funds bought or sold DNAY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-97.49	-1,000	-	-%
Apr 18, 2024	Penbrook Management LLC	sold off	-100	-141,376	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-2.09	-277,391	166,899	-%
Feb 26, 2024	Virtu Financial LLC	new	-	4,000	4,000	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-1,000	-	-%
Feb 15, 2024	DAGCO, INC.	new	-	986	986	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-42.74	-94,947	26,733	-%
Feb 14, 2024	Royal Bank of Canada	added	273	-	-	-%

Are Funds Buying or Selling DNAY?

Are funds buying DNAY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNAY

No. of Funds

Unveiling Codex DNA, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 05, 2023	broadoak fund iv, llc	10.35%	4,434,730	SC 13G/A
Jul 05, 2023	gattaca mining llc	21.28%	9,273,521	SC 13G/A
Jun 15, 2023	novalis lifesciences investments ii, l.p.	19.99%	7,419,984	SC 13D
Jun 07, 2023	northpond ventures, lp	46.7%	17,838,123	SC 13D/A
Jun 02, 2023	northpond ventures, llc	31.5%	9,375,380	SC 13D/A
Apr 19, 2023	northpond ventures, lp	31.6%	9,375,380	SC 13D/A
Feb 14, 2023	gattaca mining llc	21.2%	6,271,113	SC 13G/A
Jan 27, 2023	danaher corp /de/	7.8%	2,294,157	SC 13G/A

Recent SEC filings of Codex DNA, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	DEF 14A	DEF 14A
Apr 18, 2024	8-K	Current Report
Apr 09, 2024	PRE 14A	PRE 14A
Apr 08, 2024	8-K	Current Report
Apr 03, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading

Codex DNA, Inc. News

Latest updates

Codex DNA, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	25.4%	6,977,000	5,564,000	8,652,000	6,316,000	9,469,000	6,675,000	5,655,000	5,636,000	3,078,000	2,786,000	2,852,000	2,327,000	1,981,000	1,635,000	1,617,000
Cost Of Revenue	-13.2%	2,228,000	2,567,000	2,959,000	2,805,000	3,023,000	3,016,000	2,943,000	2,858,000	2,196,000	1,624,000	1,899,000	1,025,000	-	739,000	620,000
Gross Profit	58.5%	4,749,000	2,997,000	5,693,000	3,511,000	6,446,000	3,659,000	2,712,000	2,778,000	882,000	1,162,000	953,000	1,302,000	-	896,000	997,000
Operating Expenses	69.5%	22,230,000	13,118,000	13,659,000	14,482,000	14,330,000	14,910,000	17,199,000	15,641,000	12,979,000	10,603,000	8,525,000	7,566,000	-	5,196,000	4,293,000
S&GA Expenses	31.4%	3,604,000	2,743,000	3,360,000	3,807,000	4,108,500	4,189,000	4,688,000	3,546,000	3,087,500	2,955,000	2,630,000	2,275,000	-	1,861,000	1,598,000
R&D Expenses	-10.9%	3,669,000	4,119,000	4,587,000	5,121,000	4,707,000	5,460,000	6,950,000	6,305,000	5,249,000	3,593,000	2,746,000	2,878,000	-	2,345,000	1,955,000
EBITDA Margin	-37.4%	-1.55	-1.13	-1.17	-1.54	-1.67	-2.42	-2.83	-3.01	-3.41	-1.73	-1.95	-2.23	-2.61	-	-
Interest Expenses	117.8%	1,405,000	645,000	546,000	509,000	1,138,000	241,000	303,000	273,000	276,000	279,000	107,000	163,000	-	-	-
Income Taxes	-78.6%	3,000	14,000	4,000	3,000	6,000	6,000	6,000	6,000	4,000	4,000	2,000	4,000	-	2,000	-
Earnings Before Taxes	-66.6%	-17,684,000	-10,617,000	-8,283,000	-11,116,000	-8,126,000	-12,308,000	-14,825,000	-13,188,000	-12,487,000	-9,820,000	-9,199,000	-7,438,000	-	-4,463,000	-4,082,000
EBT Margin	-36.4%	-1.73	-1.27	-1.28	-1.65	-1.77	-2.51	-2.93	-3.11	-3.53	-1.81	-2.04	-2.34	-2.74	-	-
Net Income	-66.4%	-17,687,000	-10,631,000	-8,287,000	-11,119,000	-8,132,000	-12,314,000	-14,831,000	-13,194,000	-12,491,000	-9,824,000	-9,201,000	-7,442,000	-5,583,000	-4,465,000	-4,082,000
Net Income Margin	-36.4%	-1.73	-1.27	-1.28	-1.65	-1.77	-2.51	-2.93	-3.12	-3.53	-3.23	-3.03	-2.80	-2.74	-	-
Free Cashflow	-26.2%	-7,564,000	-5,992,000	-11,454,000	-11,637,000	-6,402,000	-15,494,000	-15,206,000	-6,081,000	-13,795,000	-12,984,000	-6,557,000	-5,216,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-33.0%	70.00	105	115	89.00	81.00	88.00	97.00	111	116	124	136	27.00
Current Assets	-42.4%	30.00	53.00	62.00	43.00	55.00	62.00	72.00	88.00	93.00	117	127	17.00
Cash Equivalents	-91.0%	2.00	17.00	47.00	23.00	30.00	25.00	22.00	31.00	83.00	110	124	13.00
Inventory	-5.7%	4.00	4.00	4.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	1.00	1.00
Goodwill	-76.5%	3.00	15.00	15.00	15.00	15.00	15.00	14.00	14.00	14.00	4.00	3.00	3.00
Liabilities	-30.2%	41.00	59.00	58.00	53.00	35.00	35.00	33.00	33.00	25.00	22.00	24.00	13.00
Current Liabilities	-67.8%	8.00	25.00	10.00	11.00	13.00	13.00	18.00	16.00	10.00	8.00	7.00	6.00
Long Term Debt	1.9%	5.00	5.00	20.00	20.00	20.00	19.00	11.00	12.00	14.00	14.00	14.00	3.00
LT Debt, Current	-100.0%	-	15.00	-	-	-	-	4.00	2.00	1.00	1.00	-	1.00
LT Debt, Non Current	1.9%	5.00	5.00	20.00	20.00	20.00	19.00	11.00	12.00	14.00	14.00	14.00	3.00
Shareholder's Equity	-98.7%	0.00	18.00	28.00	37.00	47.00	53.00	65.00	78.00	91.00	103	112	-
Retained Earnings	-12.3%	-161	-143	-133	-124	-113	-105	-93.29	-78.46	-65.27	-52.78	-42.95	-26.31
Additional Paid-In Capital	0.1%	162	162	161	161	160	159	158	157	156	156	155	1.00
Shares Outstanding	0.3%	30.00	30.00	30.00	30.00	30.00	29.00	29.00	29.00	29.00	14.00	7.00	5.00
Float	-	-	-	14.00	-	-	-	17.00	-	-	-	201	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-24.2%	-7,312	-5,888	-10,300	-11,167	-5,639	-15,103	-12,351	-5,622	-12,439	-12,651	-6,491	-5,117	-	-	-
Share Based Compensation	-46.7%	616	1,156	1,035	1,156	1,246	915	1,118	448	508	365	146	67.00	-	-	-
Cashflow From Investing	128.0%	6,495	-23,208	6,846	4,123	11,209	13,724	2,943	-45,883	-14,542	-333	-66.00	-99.00	-	-	-
Cashflow From Financing	-14772.3%	-15,021	-101	26,705	-18.00	108	4,013	331	58.00	-15.00	-985	112,494	9,587	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DNAY Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 27,509	$ 27,435
Cost of revenue	10,559	11,840
Gross profit	16,950	15,595
Operating expenses:
Research and development	17,496	23,460
Sales and marketing	13,514	16,489
General and administrative	21,090	22,131
Goodwill impairment	11,389	0
Total operating expenses	63,489	62,080
Loss from operations	(46,539)	(46,485)
Other (expense) income, net:
Interest income	1,743	738
Interest expense	(3,105)	(1,955)
Change in fair value of derivative liabilities	331	8
Loss on extinguishment of debt		(727)
Other expense, net	(130)	(26)
Total other expense, net	(1,161)	(1,962)
Loss before provision for income taxes	(47,700)	(48,447)
Provision for income taxes	(24)	(24)
Net loss	(47,724)	(48,471)
Less: redeemable convertible preferred stock dividends	(1,300)
Net loss attributable to common stockholders	$ (49,024)	$ (48,471)
Net loss per share attributable to common stock holders
Basic (in dollars per share)	$ (1.64)	$ (1.65)
Diluted (in dollars per share)	$ (1.64)	$ (1.65)
Weighted average common stock outstanding
Basic (in shares)	29,849,832	29,463,361
Diluted (in shares)	29,849,832	29,463,361
Net loss	$ (47,724)	$ (48,471)
Unrealized gain (loss) on available-for-sale short-term investments	6	(3)
Foreign currency translation loss	(3)
Total comprehensive loss	(47,721)	(48,474)
Product revenue
Revenue:
Total revenue	9,691	10,913
Service revenue
Revenue:
Total revenue	6,291	7,121
Collaboration revenue
Revenue:
Total revenue	8,690	6,650
Royalties and other revenue
Revenue:
Total revenue	$ 2,837	$ 2,751

DNAY Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,570	$ 30,419
Restricted cash	175	175
Short-term investments	17,588	13,159
Accounts receivable, net of allowance for credit losses of $1,287 and $343 at December 31, 2023 and 2022, respectively	5,985	5,851
Inventory, net	4,025	2,200
Prepaid expenses and other current assets	1,008	3,288
Total current assets	30,351	55,092
Property and equipment, net	7,300	6,861
Right-of-use assets	27,220	1,660
Other long-term assets	676	981
Goodwill	3,497	14,886
Other intangible assets, net	1,367	1,882
Total Assets	70,411	81,362
Current liabilities:
Accounts payable	3,284	1,295
Accrued employee expenses	2,142	5,858
Finance lease liability, current portion	112	59
Operating lease liability, current portion	1,710	578
Deferred revenue, current portion	338	3,958
Other accrued liabilities	506	1,377
Other current liabilities	92	373
Total current liabilities	8,184	13,498
Finance lease liability, net of current portion	147	30
Operating lease liability, net of current portion	27,142	1,111
Notes payable, net of discount	5,269	19,649
Derivative liabilities	36	367
Deferred revenue, net of current portion	95	142
Total liabilities	40,873	34,797
Commitments and contingencies (Note 15)
Preferred stock, $0.0001 par value; 5,000,000 shares authorized: Redeemable convertible preferred stock, 280,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively; liquidation preference of $29,300 and $0 at December 31, 2023 and 2022, respectively	29,300	0
Stockholders' equity
Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2023 and 2022, respectively; 30,063,322 and 29,647,091 shares issued and outstanding at December 31, 2023 and 2022, respectively	5	5
Additional paid-in capital	161,698	160,304
Accumulated other comprehensive loss		(3)
Accumulated deficit	(161,465)	(113,741)
Total stockholders' equity	238	46,565
Total liabilities, redeemable convertible preferred stock and stockholders' equity	$ 70,411	$ 81,362

About Codex DNA, Inc.

WEBSITE	https://codexdna.com

Codex DNA, Inc. Frequently Asked Questions

What is the ticker symbol for Codex DNA, Inc.? What does DNAY stand for in stocks?

DNAY is the stock ticker symbol of Codex DNA, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codex DNA, Inc. (DNAY)?

As of Thu May 02 2024, market cap of Codex DNA, Inc. is 10.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNAY stock?

You can check DNAY's fair value in chart for subscribers.

What is the fair value of DNAY stock?

You can check DNAY's fair value in chart for subscribers. The fair value of Codex DNA, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Codex DNA, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Codex DNA, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNAY is over valued or under valued. Whether Codex DNA, Inc. is cheap or expensive depends on the assumptions which impact Codex DNA, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNAY.

What is Codex DNA, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, DNAY's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 0.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNAY PE ratio will change depending on the future growth rate expectations of investors.